Recent Quotes (30 days)

You have no recent quotes
chg | %

DiagnoCure Inc.  

(Public, TSE:CUR)   Watch this stock  
Find more results for CUR
0.00000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.01 - 0.17
Open     -
Vol / Avg. 0.00/130,253.00
Mkt cap     -
P/E     -
Div/yield 0.17/∞
EPS -0.09
Shares 43.04M
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Jan '16) 2015
Net profit margin -320.64% -698.56%
Operating margin -332.47% -705.57%
EBITD margin - -635.20%
Return on average assets -107.25% -98.34%
Return on average equity - -
Employees 10 -
CDP Score - -

Address

4535 Wilfrid-Hamel Blvd Suite 250
QUEBEC, QC G1P 2J7
Canada
+1-418-5276100 (Phone)
+1-418-5270240 (Fax)

Website links

Description

DiagnoCure, Inc. is a biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml). Its subsidiaries include Catalyst Oncology LP, 9184-6766 Quebec Inc and 9161-6722 Quebec Inc.